# OnCo record nct06500273 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06500273/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06500273", "NCT06500273" ;
  schema:name "Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL"@en ;
  schema:alternateName "ALPHA3"@en ;
  schema:description "A phase 2 trial of Fludarabine and Cyclophosphamide in diffuse large B-cell lymphoma, run by Allogene Therapeutics, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06500273/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06500273> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-06-18" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:drugs <https://onco.cc/drugs/fludarabine/>, <https://onco.cc/drugs/cyclophosphamide/> ;
  onco:companies <https://onco.cc/companies/allogene/>, <https://onco.cc/companies/foresight-diagnostics/>, <https://onco.cc/companies/natera/> .